APRI (Aprinoia Therapeutics) Current Accrued Expense: $3.26 Mil (As of Dec. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aprinoia Therapeutics Current Accrued Expense?

Aprinoia Therapeutics APRI Current Accrued Expense is $3.26 Mil as of Dec. 2023.

Aprinoia Therapeutics's Current Accrued Expense for the quarter that ended in Dec. 2023 was $3.26 Mil.

Aprinoia Therapeutics's quarterly Current Accrued Expense increased from Dec. 2022 ($1.11 Mil) to Jun. 2023 ($3.89 Mil) but then declined from Jun. 2023 ($3.89 Mil) to Dec. 2023 ($3.26 Mil).

Aprinoia Therapeutics's annual Current Accrued Expense declined from Dec. 2021 ($2.57 Mil) to Dec. 2022 ($1.11 Mil) but then increased from Dec. 2022 ($1.11 Mil) to Dec. 2023 ($3.26 Mil).

Aprinoia Therapeutics Current Accrued Expense Related Terms

Aprinoia Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Current Accrued Expense Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Current Accrued Expense
2.57 1.11 3.26

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Current Accrued Expense 2.57 0.00 1.11 3.89 3.26

Aprinoia Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $3.26 Mil mean?
Aprinoia Therapeutics (APRI) has a Current Accrued Expense of $3.26 Mil as of Dec. 2023. Current Accrued Expense records the total amount of accrued expenses. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' Current Accrued Expense too high?
Aprinoia Therapeutics' current Current Accrued Expense is $3.26 Mil.
How does Aprinoia Therapeutics' Current Accrued Expense compare to ?
Aprinoia Therapeutics' Current Accrued Expense of $3.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current Current Accrued Expense is $3.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Current Accrued Expense of $3.26 Mil. The current Current Accrued Expense is $3.26 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Current Accrued Expense is $3.26 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.